Systemic therapy in cervical cancer: 30 years in review

Liontos, Michalis; Kyriazoglou, Anastasios; Dimitriadis, Ioannis; Dimopoulos, Meletios-Athanasios; Bamias, Aristotelis

doi:10.1016/j.critrevonc.2019.02.009

Cited by 144 publications

(119 citation statements)

References 108 publications

Supporting

Mentioning

118

Contrasting

Unclassified

Order By: Relevance

“…Consistent with the results in vitro, PRDX6 overexpression significantly increased the tumor volume and weight compared to the control (P < 0.01, Figure 6A, 6B and 6C). For example, the tumor volume of the PRDX6 overexpression group reached approximately 1600 mm 3 , which was significantly larger than that in the control group (only nearly 400 mm 3 ). In addition, the protein levels of PCNA and PRDX6 were significantly increased in PRDX6 overexpressing SiHa cells ( Figure 7A).…”

Section: Prdx6 Overexpression Promotes Tumor Growth Of Cervical Cancementioning

confidence: 78%

“…Cervical cancer remains one of the most frequently diagnosed malignancies and is still the second leading cause of cancer deaths among females worldwide [1,2] . Despite the rapid development of preventions and cures for cervical cancer, the overall prognosis for patients with advanced or recurrent cervical cancer is still discouraging [3] . Therefore, many researchers are engaged in identifying additional molecular regulators, which would likely contribute to improving the prognosis of cervical cancer.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Overexpression and biological function of PRDX6 in human cervical cancer

Pan

et al. 2020

J. Cancer

View full text Add to dashboard Cite

Background: Our previous study demonstrated that the peroxiredoxin 6 (PRDX6) protein was downregulated in squamous cervical cancer samples after neoadjuvant chemotherapy compared with the expression level before chemotherapy. However, the effect of PRDX6 on the biological behavior of cervical cancer is still uncertain. Thus, the purpose of this study was to explore the functional impacts of PRDX6 gene on the biological behavior of cervical squamous cancer cells. Methods: An immunofluorescence assay was applied to evaluate the expression difference of PRDX6 between cervical cancer tissue and normal cervical tissue samples. A lentivirus was used to upregulate and downregulate PRDX6 expression in SiHa cells. Furthermore, the role of PRDX6 on cell proliferation, apoptosis, migration and invasion was evaluated. Additionally, the effect of PRDX6 on the progression of the cervical cancer was investigated via a xenograft model in BALB/c nude mice that either overexpressed or underexpressed PRDX6. Results: The expression of PRDX6 was generally increased in cervical cancer tissues. Furthermore, the overexpression of PRDX6 stimulated the proliferation, migration and invasion of cervical squamous cancer cells, and suppressed cell apoptosis. The opposite results were also obtained after successful knockdown of PRDX6. In addition, the overexpression of PRDX6 significantly promoted the growth of cervical carcinoma in vivo. Conclusions: PRDX6 promoted the proliferation, migration and invasion, and inhibited apoptosis in cervical cancer cells, indicating that PRDX6 is an important promoter of cervical cancer tumorigenicity.

show abstract

Section: Prdx6 Overexpression Promotes Tumor Growth Of Cervical Cancementioning

confidence: 78%

Section: Introductionmentioning

confidence: 99%

Overexpression and biological function of PRDX6 in human cervical cancer

Pan

et al. 2020

J. Cancer

View full text Add to dashboard Cite

show abstract

“…Even though no statically significant differences were reached, the combination of CP shows a positive trend in terms of PFS and OS, which reinforced its role as standard of care. Unfortunately, the median OS was still around 12 months [21].…”

Section: First Linementioning

confidence: 99%

SEOM clinical guidelines for cervical cancer (2019)

et al. 2020

View full text Add to dashboard Cite

Cervical cancer (CC) is the fourth most common cancer in women worldwide, strongly linked to high-risk human papilloma virus infection. In high-income countries, the screening programs have dramatically decreased the incidence of CC; however, the lack of accessibility to them in developing countries makes CC an important cause of mortality. Clinical stage is the most relevant prognostic factor in CC. The new FIGO staging system published in 2018 is more accurate than the previous one since it takes into account the lymph node status. In early stages, the primary treatment is surgery-with some concerns recently raised regarding minimally invasive surgery because it might decrease survival-or radiotherapy, whereas concomitant chemo-radiotherapy is the conventional approach in locally advanced stages. For recurrent or metastatic CC, the combination of chemotherapy plus bevacizumab is the preferred therapy. Immunotherapy approach based on checkpoint inhibitors is evolving as the election therapy following failure to platinum therapy.

show abstract

“…High-risk human papillomavirus (HPV) types such as HPV-16 and -18 are known to cause cervical cancer through the overexpression of viral oncoproteins E6 and E7 [2]. Although the worldwide death rate from cervical cancer has declined due to the current treatment modalities, including HPV vaccines, surgery, radiation therapy, and chemotherapy, the cancer recurrence, metastasis, and the adverse drug effects remain major problems [3]. Therefore, safer and more effective therapeutic options are needed to improve the treatment of cervical cancer.…”

Section: Introductionmentioning

confidence: 99%

Pterostilbene Suppresses both Cancer Cells and Cancer Stem-Like Cells in Cervical Cancer with Superior Bioavailability to Resveratrol

et al. 2020

View full text Add to dashboard Cite

Increasing studies have reported that cancer stem cells (CSCs) play critical roles in therapeutic resistance, recurrence, and metastasis of tumors, including cervical cancer. Pterostilbene, a dimethylated derivative of resveratrol, is a plant polyphenol compound with potential chemopreventive activity. However, the therapeutic effect of pterostilbene against cervical CSCs remains unclear. In this study, we compared the anticancer effects of resveratrol and pterostilbene using both HeLa cervical cancer adherent and stem-like cells. Pterostilbene more effectively inhibited the growth and clonogenic survival, as well as metastatic ability of HeLa adherent cells than those of resveratrol. Moreover, the superior inhibitory effects of pterostilbene compared to resveratrol were associated with the enhanced activation of multiple mechanisms, including cell cycle arrest at S and G2/M phases, induction of ROS-mediated caspase-dependent apoptosis, and inhibition of matrix metalloproteinase (MMP)-2/-9 expression. Notably, pterostilbene exhibited a greater inhibitory effect on the tumorsphere-forming and migration abilities of HeLa cancer stem-like cells compared to resveratrol. This greater effect was achieved through more potent inhibition of the expression levels of stemness markers, such as CD133, Oct4, Sox2, and Nanog, as well as signal transducer and activator of transcription 3 signaling. These results suggest that pterostilbene might be a potential anticancer agent targeting both cancer cells and cancer stem-like cells of cervical cancer via the superior bioavailability to resveratrol.

show abstract

Systemic therapy in cervical cancer: 30 years in review

Cited by 144 publications

References 108 publications

Overexpression and biological function of PRDX6 in human cervical cancer

Overexpression and biological function of PRDX6 in human cervical cancer

SEOM clinical guidelines for cervical cancer (2019)

Pterostilbene Suppresses both Cancer Cells and Cancer Stem-Like Cells in Cervical Cancer with Superior Bioavailability to Resveratrol

Contact Info

Product

Resources

About